Skip to main content
main-content

01.12.2017 | Case Report | Ausgabe 1/2017 Open Access

Diagnostic Pathology 1/2017

Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report

Zeitschrift:
Diagnostic Pathology > Ausgabe 1/2017
Autoren:
Mafalda Trippel, Sara Imboden, Andrea Papadia, Michael D. Mueller, Nando Mertineit, Kirsi Härmä, Alina Nicolae, Erik Vassella, Tilman T. Rau
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13000-017-0629-0) contains supplementary material, which is available to authorized users.
Abbreviations
MSI
Microsatellite instability
TCGA
The Cancer Genome Atlas

Background

Intestinal differentiation occurring in endometrial carcinoma is rare. This phenomenon was first described by Berger et al. in 1984 [1] and was confirmed by several case reports [25], but it has not undergone implementation into the WHO classification of tumours of the uterine corpus.
According to this morphology-based taxonomy [6], there are eight accepted types of endometrial carcinoma, as follows: endometrioid carcinoma, mucinous carcinoma, serous carcinoma, clear cell carcinoma, mixed cell adenocarcinoma, undifferentiated carcinoma, dedifferentiated carcinoma and neuroendocrine tumours, with a spectrum reaching from low-grade neuroendocrine tumours up to large and small cell high-grade neuroendocrine carcinomas, similar to what has been conceptualised in other organs [7]. The three subtypes in the group of endometrioid carcinomas include cancers with squamous differentiation, as well as villoglandular and secretory carcinomas.
Intestinal differentiation in endometrial cancers has been shown to be exceedingly less common than in ovarian or endocervical cancers [8]. Meanwhile, attempts have been made to learn more from endometrial cancer by investigating the genetic background. The Cancer Genome Atlas Research Network (TCGA) recently postulated a classification according to genomic features into four categories, which are the following: polymerase ε (POLE) ultramutated, microsatellite instability hypermutated, copy-number low and copy-number high [9]. However, the analysis was mostly restricted to classical endometrioid adenocarcinomas and to a lesser extent to serous carcinomas of the endometrium. Other subtypes have been sofar excluded [9].
The microsatellite instable hypermutated tumours are either associated with Lynch syndrome bearing a germline mutation in one of the mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) or tumours characterised by sporadic hypermethylation of the MLH1 promotor with subsequent blockade of the transcription process and loss of protein expression [6, 10].
However, the correlation between the phenotype and genotype of endometrial cancers is difficult, and there are some very rare subtypes of endometrial carcinoma that are not well represented by these classifications.
We present herein a case of a mucinous adenocarcinoma of the endometrium with morphological and molecular features that resemble an MSI-high adenocarcinoma of the colon.

Case presentation

Clinical history

A 62-year-old woman, mother of one child from two pregnancies, presented to our hospital with recent postmenopausal bleeding. She disclosed no intake of hormonal therapy.
The past medical history was unremarkable with an appendectomy in her adolescence, menarche at the age of 12 and menopause starting around the age of 52. Her body mass index was 21.5. The family history presented two cousins with breast cancer at 45 years old and an unknown gynaecological cancer, respectively. In the first degree family members, no relevant disease was present.
Initial diagnostics consisted of a preoperative endometrial biopsy and an abdominal CT scan. The latter revealed a mass with clear enlargement of the corpus uteri with serometra, suspicion of infiltrative growth into adjacent organs and no evidence of lymph node or distant metastases (Fig. 1a).
A total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and radical pelvic lymph node dissection was performed. During surgery, extensive exploration of the abdominal organs took place (Fig. 1b).
The post-surgical course was uneventful and the patient was discharged on post-operative day 5. There was no evidence of a gastrointestinal tumour in subsequent gastroscopy, colonoscopy and colposcopy.
Based on the initially completed surgical treatment, no adjuvant treatment was recommended at the interdisciplinary tumour board in accordance with the current guidelines.
Sixteen months after the initial diagnosis, the patient presented herself with back pain and 10 kg of weight loss. A CT scan was performed, which revealed recurrent disease in the pelvis; peritoneal carcinosis was diagnosed. Again, no gastrointestinal primary tumour was evident. The patient refused further diagnostics such as biopsy as well as palliative chemotherapy. She deceased 21 months after initial diagnosis under best supportive care in a palliative care unit.

Methods

Sections (3 μm thick) were deparaffinised and processed according to routine protocols; details are provided in Table 1. Molecular MSI testing and MLH1 promotor methylation analysis followed standard protocols for Lynch syndrome testing, as published previously [11] with only slight modifications. DNA was extracted using the EZ1 tissue kit and the BioRobot EZ1 workstation (Qiagen, Hilden, Germany). HPV specific PCR was performed according to routine protocols. Six microsatellite markers were assessed as recommended (BAT25, BAT26, D2S123, D17S250, D5S346 and BAT40), and MLH1 methylation status was quantified after bisulfite treatment and corresponding pyrosequencing (bisulfite and pyrosequencing kits, Qiagen, Hilden, Germany).
Table 1
Antibodies used for immunohistochemistry
Target
Clone
Company
Dilution
Incubation
CDX2
EPR2764Y
CellMarque
1:400
15 min
CK20
Ks 20.8
CellMarque
1:800
15 min
CK7
OV-TL 12/30
CellMarque
1.800
15 min
Oestrogen
EP1
DAKO
1:50
30 min
MLH1
ES05
Novocastra
1:200
15 min
MSH2
G219-1129
CellMarque
1:500
15 min
MSH6
PU29
Novocastra
1:100
15 min
p16
E6H4
Ventana
1:5
15 min
Pax8
polyclonal
Proteintech
1:200
15 min
PMS2
A16-4
BD Pharmingen
1:100
15 min
Progesterone
16+ SAN27
Novocastra
1:1600
30 min
WT1
6 F-H2
CellMarque
1:100
15 min
AFP
polyclonal
DAKO
1:1600
15 min
SALL4
6E3
Biocare Medical
1:400
15 min
Gypican 3
1G12
CellMarque
1:200
30 min

Gross features

Macroscopically, the uterus showed a 4.0 × 3.5 × 2.0 cm tumour in the fundus with a glassy mucinous cut surface, with infiltration into the inner half of the myometrium and no extension into the lower uterine segment and cervix. The ovaries and fallopian tubes were unremarkable.

Microscopic features

Histologically, the tumour was confined to the uterine cavity. No other neoplasias were present in both ovaries, tubes and the cervix – including no evidence for premalignancies (CIN, AIS). This uterine tumour presented as mucinous adenocarcinoma limited to the inner half of the myometrium with infiltrating borders and lymphatic vessel invasion (Fig. 2 a, b).
The tumour consisted predominantly of highly atypical epithelial cells with a predominantly solid and cribriform growth pattern with abundant extracellular mucin. Applying the regular endometrial grading system, the tumour would have been judged as moderately differentiated (G2), but grading was not finally confirmed due to the intestinal differentiation. Intra-tumoural lymphocytes were slightly increased. Presumably due to tumoural overgrowth we neither found endometrial intraepithelial neoplasi nor intestinal metaplasia nor morula formation as putative precursor lesions.
We observed invasion of small lymphatic vessels, but no evidence of blood vessel invasion nor lymph node or distant metastases. The final staging was defined as: pT1a pN0(0/32) L1 V0 Pn0 Gx R0, FIGO IA.

Immunohistochemistry

Immunophenotypically (Fig. 2 c-f), the tumour was positive for CDX2 in clusters of up to 60% of tumour cells with partial expression of cytokeratin 7 and cytokeratin 20 in parallel. Cells were negative for PAX8, WT1, synaptophysin, chromogranin and vimentin, as well as for oestrogen and progesterone hormone receptors. Only scattered cells were positive in p16 staining. Yolk sac tumour antigens like AFP, SALL4 and Glypican3 were negative. Interestingly, we observed a complete loss of the mismatch repair proteins MLH1 and PMS2 with retained nuclear expression of MSH2 and MSH6.

Molecular pathology

According to the molecular analysis, all gene loci of the tumour cells showed a high grade of microsatellite instability and strong hypermethylation of the MLH1 promotor. Additionally, no HPV related DNA was detectable in the tumour.

Discussion

In the female genital tract, mucinous carcinoma can arise in the vagina, cervix, ovaries and endometrium. Intestinal differentiation seems to be quite common, especially in mucinous adenocarcinomas of the cervix and ovary, with rates up to 25% [8]. This does not account for mucinous carcinoma of the endometrium. The morphological and immunohistochemical evidence for intestinal differentiation in endometrial cancer has only reached the level of single cases [13, 5, 8, 12].
The current case of a postmenopausal woman with a hormone receptor negative tumour falls within the spectrum of the clinically relevant group of type II endometrial cancers. In general, carcinogenesis models with the definition of premalignant conditions for type II endometrial cancers (e.g. serous or clear-cell carcinomas) are still being investigated, whereas type I endometrial cancers are believed to evolve stepwise via endometrial intraepithelial neoplasia [6]. Even though this special case of an endometrial type II cancer is extremely rare, it could be correlated to a putative metaplasia-carcinoma sequence. Hence, intestinal metaplasia of the endometrium has been reported as a rare condition and has been regarded as a possible source of malignant transformation [4, 13]. It remains unclear whether milieu factors, inflammation or infections like those known in the upper gastro-intestinal tract [14, 15] might trigger in the endometrium the aberrant expression of CDX2 and the downregulation of hormone receptors and PAX8 as Müllerian markers, but these lesions can be discussed as possible precursors of intestinally differentiated adenocarcinomas of the uterine corpus. Unfortunately, the tumour size and overgrowth masked any putative precursor lesions in the present case.
The differential diagnosis of this case included the already mentioned mucinous adenocarcinomas of other regions of the female genital tract. An extension from a cervical cancer could be excluded as well as spread from the ovaries, as both organ types were completely free of tumours and metaplastic changes. Additionally, the immunohistochemical and molecular profile excludes an HPV association (negativity for p16 and HPV-DNA, Additional file 1: Figure S1) or minour serous carcinoma elements (WT1 negativity and p53 mixed expression). CDX2 positivity was strong and homogenous and not confined to substructures like the reported CDX2 positive morules in conventional endometrioid adenocarcinoma [16]. Nonetheless, this not well-understood phenomenon could be a second putative mechanism of intestinal transdifferentiation in endometrial cancers, but seems to be less likely as no squamoid elements or morules were present.
As further differential diagnosis yolk sac tumour of the endometrium as a very rare condition could be mentioned. These tumours can aberrantly express CDX2 and form a glandular pattern [17]. In rare case reports of extra-gonadal localization in the uterus, they are described in premenopausal patients and might cause a clear cell pattern with resemblance of clear cell adenocarcinoma of the endometrium [18, 19]. As a hallmark they express immunohistochemically AFP, SALL4 and Glypican3 [17]. All these three markers were negative in our tumour (Additional file 1: Figure S1) and no morphological criteria of yolk sac tumour like Schiller-Duval bodies were present. Regarding the age of our patient, the possibility of yolk sac tumour seems to be implausible [20]. Nevertheless, some authors argue for the existence of yolk sac tumour of the endometrium in postmenopausal patients based on AFP expression [17, 21]. However, it has been shown that gastric and colorectal cancers can express AFP as well, which can be used as serological biomarker [22, 23]. Our case report points towards a simply intestinal differentiated adenocarcinoma of the uterus. As the yolk sac serves as embryological ancestor of gastrointestinal organs, there might be an immunohistochemical overlap. Possibly, genetics like the loss of chromosomal region 1p or multimodular molecular characteristics could help, if yolk sac tumour is morphologically considered [24].
As additional possibility, metastasis from the gastrointestinal tract was excluded based on the clinical and imaging studies including gastro- and colonoscopy and control staging during follow-up. Hence, the primary site as endometrial cancer could be confirmed.
The early recidive situation after 16 months and tumour related death of the patient after 21 months emphasises the aggressive course, given the fact that the only initial risk factor of staging was lymphangiosis carcinomatosa.
Previous reports on intestinal differentiation in endometrial cancer revealed heterogeneous tumour elements with interspersed goblet cells [2]. However, the current tumour completely mimicked a mucinous adenocarcinoma of the colon, which are also typically found to be right-sided and hypermutated (MSI high). This molecular status was unequivocally present in our case, with protein loss of MLH1 and PMS2 due to hypermethylation of the MLH1 promotor and functional high microsatellite instability. Thus, the tumour shared not only the morphology, but also the essential genetics of this type of colon cancer.
To the best of our knowledge, this is the first case of a sporadic MSI high endometrial cancer with intestinal differentiation. Whether this special tumour type should be graded according to the endometrial cancer system (moderate grade) or the colon cancer system (low grade) remains unclear.
The recent Cancer Genome Atlas suggests a genetically driven taxonomy of endometrial cancer. This case provides evidence that the category of MSI high hypermutated endometrial cancer might contain so far under represented morphologically diverse cancer subtypes. Of note, only endometrioid and serous carcinomas of the uterine corpus were integrated in the TCGA series. Within these pre-selected cases, little is known about the frequency of intestinal differentiation [9], but this has been reported to be less than 1% elsewhere [8]. Thus, the TCGA platform should be expanded to rare tumour entities like mucinous adenocarcinoma of the endometrium, as in the present case. Additionally, the search for similarities between carcinomas of the uterine corpus, the ovaries and the breast performed within the TCGA project [9] should include other links like gastro-intestinal differentiation and similarities to colorectal cancer.

Conclusions

In conclusion, this case is an extreme example in which genetics alone could harbour considerable overlap between morphologically completely different cancer subtypes, like this case of an MSI high intestinally differentiated mucinous adenocarcinoma of the endometrium in comparison with a conventional sporadic MSI endometrioid adenocarcinoma. Thus, thorough genotype and phenotype matching for studies in endometrial cancer is essential. As presented above, the WHO classification did not foresee an intestinal differentiated endometrial adenocarcinoma. However, reports of such carcinomas reach back more than 30 years [1] and might be connected to certain premalignant conditions [4, 13]. The link to MSI-genetics and a possible aggressive course warrant its notification as a separate rare variant of mucinous endometrium carcinoma.

Acknowledgements

The authors thank Theres Waldburger and Cornelia Schlup for excellent technical assistance. Additional thanks appertain to Dr. Greta Frick as part of the palliative care team from Diaconis Bern Switzerland and getting in contact to the patient’s relatives.

Funding

Funding was covered by the institutional budget of the Institute of Pathology, University Bern, Switzerland.

Availability of data and materials

Access to further data and material is possible as request to the Tissue Bank Bern (TBB). The regular application process will be followed according to the local and national regulations.

Authors’ contributions

MT, TTR performed histological analysis and the literature search. SI, AP and MM reviewed clinical and surgical data. KH and NM interpreted CT scans. AN critically reviewed the manuscript. EV performed molecular analysis. All authors contributed to writing and read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for participation and publication

Written informed consent for publication of their clinical details and clinical images was obtained from the relative of the patient. A copy of the consent form is available for review by the Editor of this journal.

Ethics approval

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Additional file 1: Figure S1. Additional negative immunohistochemical markers, p16 (A), AFP (B), Glypican3 (C) and SALL4 (D). (TIF 6136 kb)
13000_2017_629_MOESM1_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Diagnostic Pathology 1/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

27.06.2019 | Nebennierentumoren | CME | Ausgabe 4/2019

Tumoren der Nebenniere

Aktualisierter Überblick

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Diagnostik und Management von Gefäßmalformationen

Interdisziplinäres Teamwork gefragt

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Systemische Therapie von Sarkomen

Neue Biomarker und Therapiestrategien

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Epitheloide, biphasische und Mischtumoren des Weichgewebes